NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $10.15 +0.01 (+0.10%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcutis Biotherapeutics alerts: Email Address About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARQT alerts:Sign Up Key Stats Today's Range$9.78▼$10.3150-Day Range$8.32▼$11.0052-Week Range$1.76▼$13.17Volume3.65 million shsAverage Volume3.51 million shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$13.33Consensus RatingModerate Buy Company OverviewArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 39th PercentileArcutis Biotherapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 728th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.56) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 10.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.32% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 3.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.32% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 3.70%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.91 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Arcutis Biotherapeutics this week, compared to 5 articles on an average week.Search InterestOnly 8 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $360,910.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Stock News HeadlinesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells $107,700.00 in StockSeptember 6, 2024 | insidertrades.comPatrick Burnett Sells 1,728 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockAugust 22, 2024 | insidertrades.com Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!September 20, 2024 | Paradigm Press (Ad)Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 3.3% September 20 at 7:34 AM | americanbankingnews.comBuy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market SignalsSeptember 19 at 9:16 PM | markets.businessinsider.com6 Top Penny Stocks on RobinhoodSeptember 18 at 4:47 PM | msn.comBenjamin Graham Detailed Fundamental Analysis - ARQTSeptember 11, 2024 | nasdaq.comArcutis Biotherapeutics Rings the Opening BellSeptember 7, 2024 | nasdaq.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $3.23 at the start of the year. Since then, ARQT shares have increased by 214.2% and is now trading at $10.15. View the best growth stocks for 2024 here. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its earnings results on Wednesday, August, 14th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.06. The firm earned $30.86 million during the quarter, compared to analysts' expectations of $31 million. Arcutis Biotherapeutics had a negative net margin of 150.51% and a negative trailing twelve-month return on equity of 145.41%. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Top institutional shareholders of Arcutis Biotherapeutics include Rubric Capital Management LP (8.48%), Ensign Peak Advisors Inc (1.84%), Perceptive Advisors LLC (1.35%) and Candriam S.C.A. (1.13%). Insiders that own company stock include Life Sciences Viii L Frazier, Orbimed Advisors Llc, Todd Franklin Watanabe, David W Osborne, Patrick Burnett, Howard G Welgus, Masaru Matsuda, Larry Todd Edwards, Patricia A Turney and Scott L Burrows. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX) and BioNTech (BNTX). Company Calendar Last Earnings8/14/2024Today9/20/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Stock Price Target$13.33 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+31.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-150.51% Pretax Margin-147.90% Return on Equity-145.41% Return on Assets-51.04% Debt Debt-to-Equity Ratio1.09 Current Ratio8.46 Quick Ratio8.19 Sales & Book Value Annual Sales$132.06 million Price / Sales8.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book10.80Miscellaneous Outstanding Shares115,764,000Free Float104,766,000Market Cap$1.18 billion OptionableOptionable Beta1.18 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:ARQT) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.